©2024 Stanford Medicine
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Not Recruiting
Trial ID: NCT01631318
Purpose
Patients are invited to participate in a research study of liver perfusion (how blood flows
to the liver over time). Researchers hope to learn whether perfusion characteristics of liver
metastases may be predictive of response to treatment and whether liver perfusion
characteristics can be used to follow response to treatment. Patients were selected as a
possible participant in this study because they are identified as having liver metastases
Official Title
Pilot Technical Feasibility Study on 3D Contrast-enhanced Ultrasound Imaging and to Assess Whether Change in Ultrasound 3D Perfusion Pattern Can Predict Treatment Response
Stanford Investigator(s)
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria
- Provides written Informed Consent and is willing to comply with protocol requirements.
- Has at least 1 focal lesion in liver or kidney
- Patient may be (i) in the process of receiving treatment (1 scan session), (ii) never
treated (3 scan sessions) or (iii) changing treatment regimen/ type and/or receiving a
new form of treatment and/or has been on a treatment break ('holiday')(3 scan session)
- Is at least18 years of age.
Exclusion Criteria
- Is determined by the Investigator that the subject is clinically unsuitable for the
study.
- Known right to left cardiac shunt, bidirectional or transient.
- Hypersensitivity to perflutren.
- Hypersenstivity to the contrast agent Definity.
- Pregnant and lactating women
Intervention(s):
procedure: dynamic contrast-enhanced ultrasound imaging
device: Optical Tracking Device
device: Electromagnetic Tracking Device
drug: Perflutren
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Risa Jiron
650-736-1598